CLEAN VERSION OF THE CLAIMS PRIOR TO ELECTION

1. (Original) A method for treating strabismus, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.

2. (Original) The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

3. (Original) The method of claim 1, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.

4. (Original) The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

5. (Original) A method for treating strabismus, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.

6. (Original) A method for treating blepharospasm, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.

7. (Original) The method of claim 6, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

8. (Original) The method of claim 6, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.

9. (Original) The method of claim 6, wherein the botulinum toxin is a botulinum toxin type A.

10. (Original) A method for treating blepharospasm, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.

11. (Original) A method for treating cervical dystonia, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.

12. (Currently amended) The method of claim 11, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

13. (Currently amended) The method of claim 11, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.

14. (Currently amended) The method of claim 11, wherein the botulinum toxin is a botulinum toxin type A.

15. (Currently amended) A method for treating cervical dystonia, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.

16. (Currently amended) A method for treating neuromuscular disorders, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.

17. (Currently amended) The method of claim 16, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

18. (Currently amended) The method of claim 16, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.

19. (Currently amended) The method of claim 16, wherein the botulinum toxin is a botulinum toxin type A.

20. (Currently amended) A method for treating a neuromuscular disorder, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.

21. (Currently amended) A method for treating a cholinergic influenced secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.

22. (Currently amended) The method of claim 21, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

23. (Currently amended) The method of claim 21, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.

24. (Currently amended) The method of claim 21, wherein the botulinum toxin is a botulinum toxin type A.

25. (Currently amended) The method of claim 21, wherein the cholinergic influenced secretion is a sweat secretion.

26. (Currently amended) A method for treating a cholinergic influenced secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.

27. A method for treating a cholinergic influenced sweat secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.

28. (Currently amended) A method for treating a neuromuscular disorder or a cholinergic influenced secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein, wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.